I’ve reported previously (here) on the deutetrabenazine treatment for Huntington’s disease from Israel’s Teva. But the reason it is so effective is because Teva replaced some of the hydrogen atoms with the heavier isotope deuterium, so that more of it … Continue reading →

The SD-809 (deutetrabenazine) treatment by Israel’s Teva for Huntington disease has been approved by the US FDA. http://www.businesswire.com/news/home/20161020005246/en/Teva-Announces-FDA-Acceptance-Resubmitted-Drug-Application

I highlighted (Dec 2015) Teva’s SD-809 (deutetrabenazine) treatment for tardive dyskinesia. The disease causes uncontrollable movements in around 500,000 US patients. The second Phase III trial of the treatment produced statistically significant results. http://www.tevapharm.com/news/teva_announces_positive_top_line_data_from_second_phase_iii_study_of_sd_809_in_tardive_dyskinesia_td_09_16.aspx

The US FDA has granted Breakthrough Therapy Designation status to Israel’s Teva for its SD-809 (deutetrabenazine) treatment of patients with tardive dyskinesia, a hyperkinetic movement disorder affecting about 500,000 people in the USA. http://www.tevapharm.com/news/teva_announces_breakthrough_therapy_designation_for_sd_809_granted_by_fda_for_the_treatment_of_tardive_dyskinesia_11_15.aspx  

The US FDA has approved the application by Israel’s Teva for its SD-809 (deutetrabenazine) treatment for Huntington’s disease. SD-809 was part of Teva’s May acquisition of Auspex and has completed two Phase-III studies. http://www.tevapharm.com/news/?itemid={B77B4464-664B-4DC5-8373-F7D040CE2327}